Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 USD | +1.96% | 0.00% | -24.64% |
30/04 | In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma | CI |
10/04 | Top Premarket Gainers | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.64% | 44.9M | |
-1.17% | 102B | |
+2.87% | 96.09B | |
+2.13% | 22.28B | |
-14.77% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.21% | 16.09B | |
+8.55% | 13.83B | |
+35.75% | 11.97B |
- Stock Market
- Equities
- INAB Stock
- News IN8bio, Inc.
- IN8bio : B. Riley Starts IN8bio at Buy with $19 PT, Ascribes Value to Glioblastoma Multiforme Program